文献速递食管胃疾病与幽门螺杆菌

一线非铋剂四联伴同疗法与单胶囊铋剂四联疗法的有效性和安全性比较

Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapy.
PubMed 文献 · Aliment Pharmacol Ther · 2025-07-04

基于Hp-EuReg 2013—2024年数据,比较西班牙初治患者一线经验性伴同疗法(CT)与单胶囊铋剂四联疗法(Sc-BQT)的有效性和安全性。Sc-BQT根除率高于14天CT(94% vs 91%,p<0.001),且安全性更好;两种方案均达到≥90%的成功率。

要点

  • Sc-BQT根除率94%高于14天CT的91%(p<0.001)。
  • 14天CT使用标准剂量PPI为93%,优于Sc-BQT每6小时低剂量PPI的90%(p=0.043)。
  • Sc-BQT每8小时高剂量PPI根除率最高达98%(p=0.015)。

核心结论

  • Sc-BQT比14天CT更有效、耐受性更好且适用范围更广,两种方案均达到≥90%的成功率,Sc-BQT有利于抗菌药物管理的特性进一步支持其作为幽门螺杆菌根除一线治疗。

研究设计与样本

  • 分析欧洲幽门螺杆菌管理注册研究(Hp-EuReg;2013—2024年)中纳入的初治患者数据,共评估13787例次治疗。
  • 采用多变量logistic回归结合倾向性评分加权和bootstrap分析(10000次重复)估计修正意向性治疗的有效性和安全性。

主要发现

  • 共评估13787例次治疗:7234例次(52%)为CT-10天和14天,6553例次(48%)为Sc-BQT每6小时和每8小时给药。
  • Sc-BQT根除率高于14天CT(94% vs 91%,p<0.001)。
  • 14天CT使用标准剂量PPI的根除率为93%,高于Sc-BQT每6小时使用低剂量PPI的90%(p=0.043)。
  • Sc-BQT每8小时使用高剂量PPI的根除率最高,达98%(p=0.015)。
  • Sc-BQT依从性为94%,14天CT为93%,依从性与根除成功高度相关(p<0.001)。

关键数值与推荐

  • V西班牙幽门螺杆菌共识会议推荐14天非铋剂四联伴同疗法(CT:PPI、克拉霉素、阿莫西林和甲硝唑)或10天含铋剂四联疗法(Sc-BQT:单胶囊中含PPI、铋剂、四环素和甲硝唑)。

临床怎么用

  • Sc-BQT比14天CT更有效、耐受性更好且适用范围更广,其有利于抗菌药物管理的特性进一步支持作为幽门螺杆菌根除一线治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The V Spanish Consensus Conference on Helicobacter pylori recommended either a 14-day non-bismuth quadruple concomitant therapy (CT: proton pump inhibitor [PPI], clarithromycin, amoxicillin, and metronidazole) or a 10-day bismuth-containing quadruple therapy (Sc-BQT: PPI, bismuth, tetracycline, and metronidazole in a single capsule). The relative advantages of each remain uncertain. AIM: To compare the effectiveness and safety of first-line empirical CT versus Sc-BQT in Spain. METHODS: We analysed data from treatment-naïve patients enrolled in the European Registry on H. pylori Management (Hp-EuReg; 2013-2024). Multivariate logistic regression with propensity score weighting and bootstrap analysis (10,000 replicas) estimated modified intention-to-treat effectiveness and safety. RESULTS: We evaluated 13,787 treatments: 7234 (52%) with CT-10 and 14 days, and 6553 (48%) with Sc-BQT-every 6 and 8 h. Sc-BQT showed greater effectiveness than 14-day CT (94% vs. 91%; p < 0.001). However, 14-day CT with standard-dose PPI (93%) outperformed Sc-BQT every 6 h with low-dose PPI (90%) (p = 0.043). Sc-BQT every 8 h with high-dose PPI achieved the highest eradication (98%) (p = 0.015). Adherence was similar with Sc-BQT (94%) and 14-day CT (93%), being highly associated with eradication success (p < 0.001). Sc-BQT, particularly with low- or standard-dose PPI, had a better safety profile (p < 0.001). CONCLUSION: Sc-BQT is more effective, better tolerated, and more broadly applicable than 14-day CT. Both regimens achieved ≥ 90% success, but Sc-BQT's stewardship-friendly profile further supports its use as first-line therapy for H. pylori eradication.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nyssen OP, Montes N, Pérez-Aísa Á, et al. Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapy. Aliment Pharmacol Ther. 2025. PMID: 40616238. doi:10.1111/apt.70261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。